Certara, Inc. (NASDAQ:CERT - Get Free Report) shares dropped 4.8% on Tuesday after KeyCorp lowered their price target on the stock from $18.00 to $15.00. KeyCorp currently has an overweight rating on the stock. Certara traded as low as $10.65 and last traded at $10.60. Approximately 207,751 shares traded hands during trading, a decline of 86% from the average daily volume of 1,474,408 shares. The stock had previously closed at $11.14.
Other equities analysts have also recently issued reports about the stock. JMP Securities reaffirmed a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Morgan Stanley initiated coverage on shares of Certara in a research note on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 price target for the company. Robert W. Baird lifted their price target on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Finally, Barclays upgraded shares of Certara from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $11.00 to $14.00 in a report on Thursday, May 8th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $15.29.
View Our Latest Analysis on CERT
Institutional Investors Weigh In On Certara
Several large investors have recently modified their holdings of CERT. Charles Schwab Investment Management Inc. raised its holdings in shares of Certara by 8.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 757,392 shares of the company's stock valued at $8,066,000 after purchasing an additional 57,817 shares in the last quarter. Proficio Capital Partners LLC bought a new position in shares of Certara during the 4th quarter worth approximately $148,000. Raymond James Financial Inc. bought a new position in shares of Certara during the 4th quarter worth approximately $3,628,000. PNC Financial Services Group Inc. raised its stake in shares of Certara by 188.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 20,797 shares of the company's stock worth $221,000 after acquiring an additional 13,592 shares in the last quarter. Finally, Amundi raised its stake in shares of Certara by 222.8% during the 4th quarter. Amundi now owns 62,167 shares of the company's stock worth $685,000 after acquiring an additional 42,907 shares in the last quarter. Institutional investors own 73.96% of the company's stock.
Certara Stock Performance
The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.78 and a current ratio of 2.78. The stock has a market cap of $1.71 billion, a P/E ratio of -527.00 and a beta of 1.43. The firm's 50 day moving average is $11.32 and its 200 day moving average is $11.86.
Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.10 by $0.04. The firm had revenue of $106.00 million during the quarter, compared to analyst estimates of $104.44 million. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. Certara's revenue was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.10 EPS. Analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.
Certara Company Profile
(
Get Free Report)
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Further Reading
Before you consider Certara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.
While Certara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.